Marker Therapeutics (MRKR) announced that the Company has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas, CPRIT, to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRKR:
Questions or Comments about the article? Write to editor@tipranks.com